305 related articles for article (PubMed ID: 32139006)
1. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Diamond B; Maclachlan K; Chung DJ; Lesokhin AM; Ola Landgren C
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101140. PubMed ID: 32139006
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies in multiple myeloma; emerging patterns and future directions.
Maclachlan K; Diamond B; Maura F; Hillengass J; Turesson I; Landgren CO; Kazandjian D
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101144. PubMed ID: 32139010
[TBL] [Abstract][Full Text] [Related]
4. Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Lu SX
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101151. PubMed ID: 32139016
[TBL] [Abstract][Full Text] [Related]
5. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
6. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
[TBL] [Abstract][Full Text] [Related]
7. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
8. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Kazandjian D; Dew A; Hill E
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101150. PubMed ID: 32139015
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Sengsayadeth S; Malard F; Savani BN; Garderet L; Mohty M
Blood Cancer J; 2017 Mar; 7(3):e545. PubMed ID: 28338672
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
12. Therapy sequencing strategies in multiple myeloma: who, what and why?
Costello C; Mikhael JR
Future Oncol; 2018 Jan; 14(2):95-99. PubMed ID: 29219615
[No Abstract] [Full Text] [Related]
13. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
[TBL] [Abstract][Full Text] [Related]
15. Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto P; Montefusco V
Expert Rev Hematol; 2016 Aug; 9(8):743-51. PubMed ID: 27268855
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
18. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
[TBL] [Abstract][Full Text] [Related]
19. Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
Krishnan A; Vij R; Keller J; Dhakal B; Hari P
Am Soc Clin Oncol Educ Book; 2016; 35():210-21. PubMed ID: 27249701
[TBL] [Abstract][Full Text] [Related]
20. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A; Manz K; Pfirrmann M; Hänel M; Schwarzer AC; Prange-Krex G; Fabisch C; Knop S; Illmer T; Krammer-Steiner B; Hochhaus A; von Lilienfeld-Toal M; Mügge LO
J Cancer Res Clin Oncol; 2020 Mar; 146(3):749-759. PubMed ID: 31788741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
